MC Plus Material – 15_Overview of the FY2026 Medical Fee Revision 15. Appropriate Evaluation of Medical Technologies Page 45 – Center for Health Policy Information

News Highlights

According to “MC Plus Material – 15_Overview of the FY2026 Medical Fee Revision” released by the Center for Health Policy Information, the appropriate evaluation of medical technologies will be a focal point in the FY2026 revision. The news highlights suggest that key considerations for medical M&A and business succession include preparing for medical fee revisions, maintaining facility standards through economies of scale and dispersing the burden of capital investment, and utilizing tax incentives by transitioning to specific medical corporations or social medical corporations.

M&A Medical Editorial Department’s Perspective

The overview of the FY2026 medical fee revision, particularly the item “Appropriate Evaluation of Medical Technologies,” directly impacts the revenue structure of individual medical institutions, making it an indispensable factor when considering M&A and business succession. It is crucial to align mid-to-long-term management strategies and succession strategies with the revision cycle. There is a potential for an increasing number of cases, especially for small clinics and specialized hospitals, where maintaining facility standards and making capital investments independently becomes difficult. In such circumstances, M&A that aims to benefit from economies of scale through group formation, disperse capital investment burdens, and leverage tax incentive schemes by transitioning to specific medical corporations or social medical corporations can be an effective option for stabilizing management and ensuring business continuity. This is a phase where M&A should be considered not just as a solution to succession issues, but as a strategic approach to enhance profitability.

Points Highlighted by This News

• Analysis of the impact of “Appropriate Evaluation of Medical Technologies” in the FY2026 medical fee revision on future profitability is important.
• The effectiveness of M&A strategies that leverage economies of scale, such as maintaining facility standards and dispersing capital investment burdens through group formation.
• Consideration of business succession by utilizing tax incentive schemes, including the possibility of transitioning to specific medical corporations or social medical corporations.
• The necessity of formulating a business succession plan that aligns mid-to-long-term management strategies with the medical fee revision cycle.

Practical Questions Arising from This News

• How is the evaluation of medical technologies that our clinic focuses on, such as [e.g., advanced diagnostic imaging, specific specialized treatments], likely to change with this medical fee revision?
• If we form a group, can the current facility standards (e.g., [e.g., Ward Inpatient Basic Fee]) be maintained, and what are the benefits?
• What is the specific expected effect of tax incentives from becoming a social medical corporation? What are the hurdles for transition?

If You Feel “Should I Consult Too?”

The overview of the FY2026 medical fee revision, especially the trends regarding the evaluation of medical technologies, may affect your clinic’s future profitability. If you feel the need for mid-to-long-term management strategies that consider the revision cycle and linked business succession strategies, you should proceed with considerations including group formation through M&A and utilization of tax incentive schemes. In particular, if you have concerns about independent capital investment or maintaining facility standards, early consultation is key to finding effective options.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics with a complete success fee basis as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are accepted with strict confidentiality. Free consultation here